Celgosivir
- Generic Name
- Celgosivir
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21NO5
- CAS Number
- 121104-96-9
- Unique Ingredient Identifier
- 895VG117HN
- Indication
Investigated for use/treatment in hepatitis (viral, C).
Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
- Conditions
- Dengue Fever
- Interventions
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Singapore General Hospital
- Registration Number
- NCT02569827
- Locations
- 🇸🇬
Singhealth Investigational Medicine Unit, Singapore, Singapore
Celgosivir as a Treatment Against Dengue
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01619969
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2008-04-08
- Lead Sponsor
- BioWest Therapeutics Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00332176
- Locations
- 🇨🇦
Cantest, Vancouver, British Columbia, Canada
🇨🇦Biovail Contract Research, Toronto, Ontario, Canada
🇨🇦Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2008-01-21
- Lead Sponsor
- BioWest Therapeutics Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00292084
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-09-29
- Lead Sponsor
- BioWest Therapeutics Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00217139
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2005-09-12
- Lead Sponsor
- BioWest Therapeutics Inc
- Target Recruit Count
- 43
- Registration Number
- NCT00157534
A Study of MDL 28,574A in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoechst Marion Roussel
- Registration Number
- NCT00002329
- Locations
- 🇺🇸
Saint Francis Mem Hosp, San Francisco, California, United States
A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoechst Marion Roussel
- Target Recruit Count
- 200
- Registration Number
- NCT00002150
- Locations
- 🇺🇸
Southwest Community Based AIDS Treatment Group - COMBAT, Los Angeles, California, United States
🇺🇸Ctr for Special Immunology, Chicago, Illinois, United States
🇺🇸North Jersey Community Research Initiative, Newark, New Jersey, United States
A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoechst Marion Roussel
- Target Recruit Count
- 200
- Registration Number
- NCT00002151
- Locations
- 🇺🇸
Ctr for Special Immunology, Chicago, Illinois, United States
🇺🇸North Jersey Community Research Initiative, Newark, New Jersey, United States
🇺🇸Houston Clinical Research Network, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.